The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas
Open accessAbstract
DNAs from human pancreatic adenocarcinomas were analyzed for the presence of mutations in codons 12, 13 and 61 of the NRAS, KRAS and HRAS gene. Formalin-fixed and paraffin-embedded tissue was used directly in an in vitro amplification reaction to expand the relevant RAS sequences. The mutations were detected by selective hybridization using mutation-specific synthetic oligonucleotides. In 28 of the 30 patients we found a mutation in codon 12 of the KRAS gene. This result confirms the findings of Almoguera et al. [Cell 53 (1988) 549-554] that KRAS mutations occur frequently in adenocarcinomas of the exocrine pancreas. The mutations are predominantly G-T transversions, in contrast to the KRAS mutations in colon tumors which are mainly G-A transitions. Furthermore, in a portion of the tumors the mutation appears to be homozygous.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., van Boom, J. H., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860
Self-citationDetection of high incidence of K-ras oncogenes during human colon tumorigenesis
Forrester, K., Almoguera, C., Han, K., Grizzle, W. E., & Perucho, M. (1987) · Nature · doi:10.1038/327298a0 · Cited by 1,061
The ras gene family and human carcinogenesis
Bos, J. L. (1988) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(88)90004-8 · Cited by 782
Self-citationDetection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction.
Shibata, D. K., Arnheim, N., & Martin, W. J. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.1.225 · Cited by 707
Guanosine Triphosphatase Activating Protein (GAP) Interacts with the p21 ras Effector Binding Domain
Adari, H., Lowy, D. R., Willumsen, B. M., Der, C. J., & McCormick, F. (1988) · Science · doi:10.1126/science.2833817 · Cited by 506
The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product
Calés, C., Hancock, J. F., Marshall, C. J., & Hall, A. (1988) · Nature · doi:10.1038/332548a0 · Cited by 386
Farr, C. J., Saiki, R. K., Erlich, H. A., McCormick, F., & Marshall, C. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.5.1629 · Cited by 356
A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides
Verlaan-de Vries, M., Bogaard, M. E., van den Elst, H., van Boom, J. H., van der Eb, A. J., & Bos, J. L. (1986) · Gene · doi:10.1016/0378-1119(86)90335-5 · Cited by 336
Self-citationDietary habits and past medical history as related to fatal pancreas cancer risk among adventists
Mills, P. K., Beeson, W. L., Abbey, D. E., Fraser, G. E., & Phillips, R. L. (1988) · Cancer · doi:10.1002/1097-0142(19880615)61:12<2578::aid-cncr2820611232>3.0.co;2-0 · Cited by 297
Cited by
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Molecular subtypes of pancreatic cancer
Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0109-y · Cited by 892
K-ras Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S. S., Vanderschueren, R. G. J. R. A., van Zandwijk, N., Mooi, W. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230902 · Cited by 809
Self-citationCogoi, S., & Xodo, L. E. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl286 · Cited by 739
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells
Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., & Brady, N. R. (2015) · Oncoscience · doi:10.18632/oncoscience.160 · Cited by 524
“Thus, the here described sensitivity of PDAC cancer cells to ferroptosis suggests an alternative pathway to selectively kill pancreatic cancer cells, especially considering that mutationally-active KRas mutations drive the majority of PDAC [7, 53, 54].”
BackgroundPolymerase chain reaction: basic protocol plus troubleshooting and optimization strategies
Lorenz, T. C. (2012) · Journal of Visualized Experiments · doi:10.3791/3998 · Cited by 493
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
Roles for KRAS in Pancreatic Tumor Development and Progression
di Magliano, M. P., & Logsdon, C. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.071 · Cited by 400
Sessa, F., Solcia, E., Capella, C., Bonato, M., Scarpa, A., Zamboni, G., Pellegata, N. S., Ranzani, G. N., Rickaert, F., & Kl�ppel, G. (1994) · Virchows Archiv · doi:10.1007/bf00189573 · Cited by 361
Genetic profile of 22 pancreatic carcinoma cell lines: Analysis of K-ras, p53, p16 and DPC4/Smad4
Moore, P. S., Sipos, B., Orlandini, S., Sorio, C., Real, F. X., Lemoine, N. R., Gress, T., Bassi, C., Klöppel, G., Kalthoff, H., et al. (2001) · Virchows Archiv · doi:10.1007/s004280100474 · Cited by 329
High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomas
Grünewald, K., Lyons, J., Fröhlich, A., Feichtinger, H., Weger, R. A., Schwab, G., Janssen, J. W. G., & Bartram, C. R. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430614 · Cited by 290
Andea, A., Sarkar, F., & Adsay, V. N. (2003) · Modern Pathology · doi:10.1097/01.mp.0000087422.24733.62 · Cited by 290
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
van 't Veer, L. J., Burgering, B. M., Versteeg, R., Boot, A. J., Ruiter, D. J., Osanto, S., Schrier, P. I., & Bos, J. L. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.7.3114 · Cited by 283
Self-citationGenetic, Immunohistochemical, and Clinical Features of Medullary Carcinoma of the Pancreas
Wilentz, R. E., Goggins, M., Redston, M., Marcus, V. A., Adsay, N. V., Sohn, T. A., Kadkol, S. S., Yeo, C. J., Choti, M., Zahurak, M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65035-3 · Cited by 282
Ras gene mutation and amplification in human nonmelanoma skin cancers
Pierceall, W. E., Goldberg, L. H., Tainsky, M. A., Mukhopadhyay, T., & Ananthaswamy, H. N. (1991) · Molecular Carcinogenesis · doi:10.1002/mc.2940040306 · Cited by 278
Abraham, S. C., Wu, T.-T., Klimstra, D. S., Finn, L. S., Lee, J.-H., Yeo, C. J., Cameron, J. L., & Hruban, R. H. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63008-8 · Cited by 275
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Cicenas, J., Kvederaviciute, K., Meskinyte, I., Meskinyte-Kausiliene, E., Skeberdyte, A., & Cicenas, J. (2017) · Cancers · doi:10.3390/cancers9050042 · Cited by 272
The Pathology and Genetics of Metastatic Pancreatic Cancer
Yachida, S., & Iacobuzio-Donahue, C. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.3.413 · Cited by 269
Bremner, R., & Balmain, A. (1990) · Cell · doi:10.1016/0092-8674(90)90523-h · Cited by 264
Zhang, Y., Yan, W., Collins, M. A., Bednar, F., Rakshit, S., Zetter, B. R., Stanger, B. Z., Chung, I., Rhim, A. D., & di Magliano, M. P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1558-t · Cited by 261
Molecular prognostic markers in pancreatic cancer: A systematic review
Garcea, G., Neal, C. P., Pattenden, C. J., Steward, W. P., & Berry, D. P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.044 · Cited by 259
Agrawal, N., Jiao, Y., Sausen, M., Leary, R., Bettegowda, C., Roberts, N. J., Bhan, S., Ho, A. S., Khan, Z., Bishop, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2703 · Cited by 255
Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., & Tebbutt, N. C. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9687-4 · Cited by 236
Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas
Suwa, H., Ohshio, G., Imamura, T., Watanabe, G., Arii, S., Imamura, M., Narumiya, S., Hiai, H., & Fukumoto, M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.23 · Cited by 218
Molecular pathogenesis of pancreatic cancer
Hansel, D. E., Kern, S. E., & Hruban, R. H. (2003) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.4.070802.110341 · Cited by 159
The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1
Cullis, J., Meiri, D., Sandi, M. J., Radulovich, N., Kent, O. A., Medrano, M., Mokady, D., Normand, J., Larose, J., Marcotte, R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.025 · Cited by 100
Shin, S. H., Kim, S. C., Hong, S.-M., Kim, Y. H., Song, K.-B., Park, K.-M., & Lee, Y.-J. (2013) · Pancreas · doi:10.1097/mpa.0b013e31825b6ab0 · Cited by 107
Qiu, W., Sahin, F., Iacobuzio-Donahue, C. A., Garcia-Carracedo, D., Wang, W. M., Kuo, C.-Y., Chen, D., Arking, D. E., Lowy, A. M., Hruban, R. H., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.357 · Cited by 99
“com/oncotarget frequency in pancreatic carcinomas [3, 4].”
Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
Velez-Delgado, A., Donahue, K. L., Brown, K. L., Du, W., Irizarry-Negron, V., Menjivar, R. E., Lasse Opsahl, E. L., Steele, N. G., The, S., Lazarus, J., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.016 · Cited by 91
“More than 90% of pancreatic ductal adenocarcinoma instances harbor an oncogenic mutation in the KRAS gene, most commonly KRAS.(2,3) Autopsy studies have shown that more than 75% of the population harbors preneoplastic lesions in the pancreas that are linked to mutations in KRAS, yet pancreatic cancer is relatively rar…”
BackgroundGenetics of familial and sporadic pancreatic cancer
Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91
Ras biochemistry and farnesyl transferase inhibitors. A literature survey
Crul, M., de Klerk, G. J., Beijnen, J. H., & Schellens, J. H. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200103000-00001 · Cited by 75
Metadata
- Authors
- Smit, V. T. H. B. M., Boot, A. J. M., Smits, A. M. M., Fleuren, G. J., Cornelisse, C. J., & Bos, J. L.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1988
- Volume
- 16
- Issue
- 16
- Pages
- 7773-7782
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2064446750
- Cited by
- 626
- References
- 18
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.